Authors

Latest:

Dr. Yael Cohen on Anti-Angiogenic Agent VB-111

Yael Cohen, MD, vice president of Clinical Development at VBL Therapeutics Pharmaceuticals, discusses VB-111, a highly targeted anti-angiogenic agent that is being investigated in several tumor types.

Drew Moghanaki, MD, MPH

Latest:

Dr. Moghanaki on Remaining Questions Following the CheckMate-816 Trial in NSCLC

Drew Moghanaki, MD, MPH, discusses questions that still need to be addressed following the phase 3 CheckMate-816 trial of the neoadjuvant combination nivolumab plus chemotherapy in patients with non–small cell lung cancer.

Drug Discovery

Dung T. Le, MD

Latest:

Dr. Dung Le on Biomarker for PD-1 Agents in CRC

Dung T. Lee, MD, assistant professor of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine, discusses a biomarker for PD-1 agents in colorectal cancer (CRC).

Dungsa Chen PhD

Latest:

Phase II Clinical Trial of Intratumoral Dendritic Cells Injections and Neoadjuvant Radiotherapy in Resectable Soft Tissue Sarcomas

Neoadjuvant radiation with dendritic cell injections has the potential to be safe, effective, and immunogenic in high-grade soft tissue sarcoma and needs to be confirmed in randomized larger clinical trials.

Dustin A. Deming, MD

Latest:

Precision Medicine Modeling Helps Advance Colorectal Cancer Care

Preclinical mouse models and cell lines link colorectal cancer subtypes subtypes with potential therapies.

Dustin Deming, MD, University of Wisconsin

Dustin M. Walters, MD

Latest:

Dr. Walters on the Best Approach to Treating Patients With Stage III Lung Cancer

Dustin M. Walters, MD, assistant professor, Thoracic and Cardiovascular Surgery, University of Virginia Health System, discusses the best approach to treating patients with stage III lung cancer.

Dwight L. Fitch, MD

Latest:

Dr. Fitch Discusses Dose Escalation of Radiation in Prostate Cancer

Dwight L. Fitch, MD, Radiation Oncologist, 21st Century Oncology in Bradenton, Florida, discusses dose modifications for radiation therapy in patients with prostate cancer.

Dylann Cohn-Emery

Latest:

Palbociclib Plus Anti-HER2 and Endocrine Therapy Prolongs PFS in HR+/HER2+ Breast Cancer

Palbociclib plus anti-HER2 and endocrine therapy improved progression-free survival in hormone receptor–positive, HER2-positive metastatic breast cancer.

E. David Crawford, MD

Latest:

Dr. Crawford on Ongoing Trials of Genetic Testing for Prostate Cancer

E. David Crawford, MD, professor of Radiation Oncology, University of Colorado School of Medicine, discusses ongoing trials regarding genetic testing for patients with prostate cancer.

E. David Crawford, MD, & Kyle O. Rove, MD

Latest:

Advanced Prostate Cancer: Therapeutic Sequencing, Outcomes, and Cost Implications

There is a dramatic revolution under way in the treatment of advanced-stage prostate cancer, which for many years consisted of systemic chemotherapy that offered only palliation of symptoms and no hope of improved survival.

E. David Crawford, MD, Neal D. Shore, MD

Latest:

Beyond PSA: A Summary Review of Predictive/Prognostic Biomarkers in Prostate Cancer

Although prostate cancer (PC) is the most common solid tumor malignancy among men in the Western Hemisphere, disease-specific mortality remains low, primarily due to optimized screening, diagnosis, and treatment.

E. David Crawford, MD, University of Colorado

E. David Crawford, MD, University of Colorado in Denver

E. Gabriela Chiorean, MD, SCCA

Latest:

Poised Potential With Zenocutuzumab in NRG1+ Pancreatic Cancer

E. Gabriela Chiorean, MD, of Fred Hutch Cancer Center, discusses the recent clinical data with zenocutuzumab in patients with NRG1 fusion–positive pancreatic cancer and the impact the approval of this agent could have on the landscape.

E. Roy Berger, MD

Latest:

What to Look for in this Issue

The landscape for managing prostate cancer is changing rapidly. In recent months, we have seen two new drugs approved for hormone refractory advanced disease

E. Roy Berger, MD, FACP

Latest:

A Riddle, Wrapped in a Mystery, Inside an Enigma

At last year's American Society of Clinical Oncology (ASCO) meeting, the official focus was on seeing personalized cancer medicine translated from a theoretical approach to a practical one. As you will see in this issue of Oncology & Biotech News, success is being realized on this front.

Earle Burgess, MD

Latest:

Dr. Burgess on the Integration of PARP Inhibitors in Prostate Cancer

Earle Burgess, MD, discusses the integration of PARP inhibitors in advanced prostate cancer.

Ed Rabinowitz

Latest:

Rx for Protection Rather Than For Cure

Physicians tend to agree that the practice of defensive medicine is widespread, especially in oncology where much more is at stake than in the general practitioner's office. However, things can go drastically wrong.